Romidepsin (FK228, Depsipeptide)

For research use only.

Catalog No.S3020 Synonyms: FR 901228, NSC 630176

112 publications

Romidepsin (FK228, Depsipeptide) Chemical Structure

Molecular Weight(MW): 540.7

Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively. Romidepsin (FK228/depsipeptide) controls growth and induces apoptosis in neuroblastoma tumor cells.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 1638 In stock
USD 157 In stock
USD 477 In stock
USD 697 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Romidepsin (FK228, Depsipeptide) has been cited by 112 publications

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively. Romidepsin (FK228/depsipeptide) controls growth and induces apoptosis in neuroblastoma tumor cells.
Features More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.
Targets
HDAC1 [1]
(Cell-free assay)
HDAC2 [1]
(Cell-free assay)
36 nM 47 nM
In vitro

Unlike TSA, the active form redFK of Romidepsin strongly inhibits HDAC1 and HDAC2 with IC50 of 1.6 nM and 3.9 nM, respectively, but is relatively weak in inhibiting HDAC4 and HDAC6 with IC50 25 nM and 790 nM, respectively. Romidepsin is 17-23 times weaker than redFK in inhibiting these HDACs with IC50 of 36 nM, 47 nM, 510 nM, and 14 μM, respectively. Romidepsin treatment in HeLa cells induces histone acetylation and p21 expression with EC50 of 3.0 nM, more strongly than redFK with EC50 of 11 nM due to the instability of redFK. [1] In addition to G2/M arrest, Romidepsin treatment causes cyclin D1 downregulation and a p53-independent p21 induction, leading to inhibition of CDK and dephosphorylation of Rb resulting in growth arrest in the early G1 phase. [2] Romidepsin is 100 times more potent than TSA and 1,000,000 times more potent than butyrate in inhibiting the proliferation of the A549 cells. [3] Romidepsin inhibits the growth of U-937, K562, and CCRF-CEM cells with IC50 of 5.92 nM, 8.36 nM, and 6.95 nM, respectively. [5] Romidepsin promotes apoptosis in chronic lymphocytic leukemia (CLL) cells at a concentration corresponding to that at which H3 and H4 acetylation and HDAC inhibition occurs, selectively involving activation of caspase 8 and effector caspase 3, as well as down-regulation of c-FLIP protein. [6] In 11 of 13 (85%) renal cell carcinoma cell lines and in 16 of 37 (43%) other cancer cell lines, Romidepsin treatment up-regulates tumor death receptors, and potentiates natural killer (NK)-mediated tumor killing. [7] Romidepsin exhibits concentration-dependent cytotoxicity against a panel of mantle cell lymphoma (MCL) cell lines. [9]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SU-DHL4 MULD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NYi5[GVvOi53LUG1JI5O NHzDdo04OiCq MXjpcoR2[2W|IHP5eI91d3irY3n0fUBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7lduKh NHvBU|czPTd7MEmwOy=>
U2932  NUTaTIw4S2WubDDWbYFjcWyrdImgRZN{[Xl? NWDM[pZxOi53LUG1JI5O NHLWPJM4OiCq NFXFWWJqdmS3Y3XzJIN6fG:2b4jpZ4l1gSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5mesLi NX;DOVFvOjV5OUC5NFc>
OCI-LY7 MXXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MkD1Nk42NTF3IH7N NWjMSWVnPzJiaB?= MXfpcoR2[2W|IHP5eI91d3irY3n0fUBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7lduKh NXTtenJ[OjV5OUC5NFc>
Farage MmLOR4VtdCCYaXHibYxqfHliQYPzZZk> MWSyMlUuOTVibl2= NGfjbHQ4OiCq NH3U[HZqdmS3Y3XzJIN6fG:2b4jpZ4l1gSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5mesLi NIjWbWEzPTd7MEmwOy=>
LY7/EBV Ml;zR4VtdCCYaXHibYxqfHliQYPzZZk> NEizVHQzNjVvMUWgcm0> Mmn0O|IhcA>? NUPrVYM{cW6mdXPld{BkgXSxdH;4bYNqfHliaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XMEoB?= M4HreFI2PzlyOUC3
U2932/EBV NVPlZZF7S2WubDDWbYFjcWyrdImgRZN{[Xl? MmfMNk42NTF3IH7N NUixeIQ3PzJiaB?= NYO0[nA2cW6mdXPld{BkgXSxdH;4bYNqfHliaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XMEoB?= NYrocHpKOjV5OUC5NFc>
HCT116 M3jIPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUGw[|RlPS13MECwJI5O Ml;hNlQhcA>? MXXEUXNQ MXLpcoR2[2W|IHPlcIwh\GWjdHigbY4h[SClb37j[Y51emG2aX;uMYRmeGWwZHXueEBu[W6wZYK= MV[yOVQ6OjVzNR?=
ACH-2 M2LWXGZ2dmO2aX;uJGF{e2G7 NEnGUlYyNTlibl2= NUfI[3FvOjRiaB?= MUXpcoR2[2W|IFjJWk0yKEWwdjDlfJBz\XO|aX;u MnTsNlUyPDl2Nke=
MCF-10A NV3SXmVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TT[GlEPTB;MD6xO:KyOC5yMTDuUS=> NEDMRm8zPDl3NEi1Oi=>
MCF-7 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzTTWM2OD1zLkGwxtExNjJyIH7N MViyOFk2PDh3Nh?=
SK-BR-3 NIHKXIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYOxSXdVUUN3ME2xMlAxyrFyLkO1JI5O NHv5PGszPDl3NEi1Oi=>
MDA-MB-231 NXnhZlhKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTBwNklCtVAvOTRibl2= M1zkUVI1QTV2OEW2
PC3 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvhTYtyUUN3ME2xMlY2yrFyLkO1JI5O Mn\QNlQ6PTR6NU[=
HCT116 NVXRcoxrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTFwMEFCtVAvODBibl2= NXzrU5FPOjR7NUS4OVY>
HCT116-p21-/- NFfUc2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXpTWM2OD1zLkK2xtExNjN5IH7N MnmyNlQ6PTR6NU[=
S1 M2nmeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTdwNkhCtVAvOjlibl2= MnHzNlQ6PTR6NU[=
SW620 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzUZYdkUUN3ME2wMlk{yrFyLkK5JI5O M2HSe|I1QTV2OEW2
LOX-IMVI MnyyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnz1TWM2OD1yLki3xtExNjB|IH7N M3[wRlI1QTV2OEW2
UACC-62 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfNTWM2OD1yLkW2xtExNjF4IH7N Mln2NlQ6PTR6NU[=
MDA-MB-435 NFXXZlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnZdHN3UUN3ME2wMlkxyrFyLkC2JI5O MoG4NlQ6PTR6NU[=
SF-295 M3jjcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTBwOElCtVAvOTVibl2= NFy2cpczPDl3NEi1Oi=>
A549 M4Xs[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoS2TWM2OD1zLkK2xtExNjJ2IH7N NYnrNFNpOjR7NUS4OVY>
H460 MkC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jPRmlEPTB;Mj61POKyOC56MDDuUS=> MYSyOFk2PDh3Nh?=
EKVX NYLtUYZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DvTWlEPTB;MT6zN:KyOC5|NDDuUS=> M2r6bVI1QTV2OEW2
H146 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnxPWZwUUN3ME2wMlIzyrFyLkC3JI5O MlyxNlQ6PTR6NU[=
H526 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPKV|NNUUN3ME2wMlE2yrFyLkCzJI5O M{\VPVI1QTV2OEW2
HuT-78 M2XweGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfNepJKSzVyPUGuO|PDuTBwNESgcm0> M3fwWVI1QTV2OEW2
HA NEntZ4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{Tte|AvPjJ3LUGwcm0> Mn7pOFghcA>? MmTsbY5lfWOnczDhJJNq\26rZnnjZY51dHlic4Tyc45o\XJiaX7obYJqfGmxbjDv[kBk\WyuIIDyc4xq\mW{YYTpc44h[29vdILlZZRm\CC5aYToJIJwenSnen;tbYI> MXKyOFc4OTVzMB?=
MS-275 NWHUb5R[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWWwMlYzPS1zMH7N M4DpPFQ5KGh? MUXpcoR2[2W|IHGgd4lodmmoaXPhcpRtgSC|dILvcodmeiCrbnjpZol1cW:wIH;mJINmdGxicILvcIln\XKjdHnvckBkdy22cnXheIVlKHerdHigZo9zfGW8b33pZi=> NX;jOHVVOjR5N{G1NVA>
CD4 T MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUX2dnVtPDhiaB?= NUjhRmloTUN3ME20MlXDuTFwMDDuUS=> MVKyOFczOjR3NB?=
CD4 T Ml;JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHkcoQ1QCCq M{j4U2NEPTB;MUC3xtEyOjZibl2= Mnv4NlQ4OjJ2NUS=
CD4+ T NVjic4tKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPESWM2OD1|IH7N NH;YVowzPDR7NUGwOS=>
A549 NEXjNlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHVNVDjiJNzMEFCpI5O MmnTNlQwOzZxNEigbC=> NI\vbWxqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKGOxbnPlcpRz[XSrb36tJIFv\CC2aX3lMYRmeGWwZHXueEBu[W6wZYK= M2rmR|I1PDh3N{m5
JJN3 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVWyOE81QCCq M3HCSWVEPTB:MfMAjY5OQyB2OPMAjYg> M4XVdFI1ODNyMUWw
OPM-2 NEPlRXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYSyOE81QCCq Mnj5SWM2OHN;MfMAjY5OQyB2OPMAjYg> M3;sfVI1ODNyMUWw
RPMI-8226 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXmyOE81QCCq MYfFR|Uxez1zLklihKlvVTtiNElihKlp NHWxNlEzPDB|MEG1NC=>
U266 NIK0TmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU[yOE81QCCq MmLYSWM2OHN;MUFihKlvVTtiNElihKlp NULSbYFpOjRyM{CxOVA>
CA46 MY\BdI9xfG:|aYOgRZN{[Xl? NX70Spl4PiCq M3ix[olv\HWlZYOgZox2dnRiYYDvdJRwe2m| MY[yN|k3PjF4NB?=
DG75 NEDVNVJCeG:ydH;zbZMhSXO|YYm= NGHmZ5Y3KGh? NUfMcldZcW6mdXPld{BvdyCjcH;weI9{cXN? NGrCUZUzOzl4NkG2OC=>
Ramos NHPIOFlCeG:ydH;zbZMhSXO|YYm= M4T1NFYhcA>? NGLxTZBqdmS3Y3XzJIV5fGWwc3n2[UBieG:ydH;zbZM> M1i5WVI{QTZ4MU[0
ST486 NEL3TplCeG:ydH;zbZMhSXO|YYm= NGXRTJk3KGh? MmXObY5lfWOnczDlfJRmdnOrdnWgZZBweHSxc3nz M4DmZ|I{QTZ4MU[0
HuT78 MYrBdI9xfG:|aYOgRZN{[Xl? MlrhNU8yOC9zMECgcm0> NXz5XGVZPDhiaB?= NXnvbZB1cW6mdXPld{BieG:ydH;zbZMh[XRiMTDuUS=> MknuNlM2OzJ5M{K=
DpVp35 MmnwRZBweHSxc3nzJGF{e2G7 Mn;1NU8yOC9zMECgcm0> MXe0PEBp MlqxbY5lfWOnczDicJVvfCCjcH;weI9{cXN? M1e5SlI{PTN{N{Oy
DpVp50 MY\BdI9xfG:|aYOgRZN{[Xl? NFft[moyNzFyL{GwNEBvVQ>? M1zUbFQ5KGh? MUjpcoR2[2W|IHLseY51KGGyb4D0c5Nqew>? NXTIPFRiOjN3M{K3N|I>
DpP75  MXTBdI9xfG:|aYOgRZN{[Xl? MYGxM|ExNzFyMDDuUS=> MYO0PEBp MXzpcoR2[2W|IHLseY51KGGyb4D0c5Nqew>? NGK5bWMzOzV|MkezNi=>
SKOV-3 Mn;TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XQTlHjiJN{MH7N NXGwdmNJPzJiaB?= Mmr6SG1UVw>? MWfy[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGGub37lJIFv\CClb33ibY5m\CC5aYToJINqe3CuYYTpci=> NFnmV|EzOzBzMEO0PC=>
Brca1 WT NI\I[GpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7TSJky6oDVMkDuUS=> MYW3NkBp M3HKbmROW09? NIX5eYNz\WS3Y3XzJINmdGxidnnhZoltcXS7IHHsc45mKGGwZDDjc41jcW6nZDD3bZRpKGOrc4DsZZRqdg>? Mn;wNlMxOTB|NEi=
Brca1 Null NXHvZYZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fPT|HjiJN{MH7N MmTlO|IhcA>? NHLGWGZFVVOR MXXy[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGGub37lJIFv\CClb33ibY5m\CC5aYToJINqe3CuYYTpci=> NHXjOWozOzBzMEO0PC=>
OVCAR-8  MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XMNFHjiJN{MH7N MYW3NkBp NV3jO4t[TE2VTx?= MYDy[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGGub37lJIFv\CClb33ibY5m\CC5aYToJINqe3CuYYTpci=> MXGyN|AyODN2OB?=
NCI/ADR-RES MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnJdoY5OeLCk{Kwcm0> MmG1O|IhcA>? NHHH[pBFVVOR M4XybJJm\HWlZYOgZ4VtdCC4aXHibYxqfHliYXzvcoUh[W6mIHPvcYJqdmWmIIfpeIgh[2m|cHzheIlv MlvSNlMxOTB|NEi=
HCT116 MoLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTQOUBvVS13MDFOwG0> M4LUWlI1KGh? M4nsbGROW09? M37PN4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz NIn0PYYzOjl{NEm1PC=>
RKO NF;Fb2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nLfVUhdk1vNUCg{txO NXrEN5Y6OjRiaB?= NWfYc3JuTE2VTx?= M{HkUolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz M4D4elIzQTJ2OUW4
CO115 MnfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrBcnM2KG6PLUWwJO69VQ>? NGC4cW8zPCCq MYrEUXNQ NYfFRYZvcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XJ? NFftUGkzOjl{NEm1PC=>
HFS MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknZOUBvVQ>? NVLV[lBrOjRxNEivO|IhcA>? MnfobY5pcWKrdIOgZ4VtdCCpcn;3eIghfGmvZT3k[ZBmdmSnboTsfS=> MljnNlIyODZ{OEK=
LNCaP MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfYdo5VPSCwTR?= M4nkXlI1NzR6L{eyJIg> MWnpcohq[mm2czDj[YxtKGe{b4f0bEB1cW2nLXTldIVv\GWwdHz5 Ml7zNlIyODZ{OEK=
A549 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYS1JI5O MUGyOE81QC95MjDo NX61dHVScW6qaXLpeJMh[2WubDDndo94fGhidHnt[U1l\XCnbnTlcpRtgQ>? M4TI[VIzOTB4Mkiy
697  Mnz5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|Ux6oDLPfMAjVIvPcLibl2= M3\WblIyPTN6MkG2
697-R MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4L5OWlEPTEkgJm95qCKQC54wrDuUeKh NWPD[JlqOjF3M{iyNVY>
HUT78 M4fLdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TRZWlEPTB;MTDuUS=> MojRNlEyQTh3NEW=
THJ-16T M3H1NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWqxJI5O NWO0bnZvOjRiaB?= NH\RcHFqdmirYnn0d{Bk\WyuIHfyc5d1cA>? M1XqUFIxQDFyNU[4
HCT116 MXLGeY5kfGmxbjDBd5NigQ>? NVToXJRTOjBibl2= Ml3CPEBp MVrtc4R2dGG2ZYOgeJJidnOlcnnweEBt\X[nbIOg[o9zKGi3bnTy[YR{KG:oIHflcoV{KGmwIHXpeIhmeiCmaYLlZ5Rqd25? Mlq4NlA4Ozl2NUS=
B104  MlPvSpVv[3Srb36gRZN{[Xl? MUiyJI5O NVvRNpZFOjRxNEivO|IhcA>? NYfKe4I2cW6lcnXhd4V{KHSqZTDzeZJn[WOnIHX4dJJme3Orb36gc4YhS0R{MNMg M4rHXVIxPjh4NUC1
HL-60  MmXER5l1d3SxeHnjbZR6KEG|c3H5 NVLnbXJ6OS13MECgcm0> NIPNfoEzPCCq MWXpcoR2[2W|IHP5eI91d3irY3n0fUBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7lduKh NI\rNZczODZ{NEG2Ny=>
HP100 NF3CeJVEgXSxdH;4bYNqfHliQYPzZZk> MXmxMVUxOCCwTR?= NFTWbJUzPCCq MnP4bY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? NFrPd|YzODZ{NEG2Ny=>
HL-60  NUHDW5dlTnWwY4Tpc44hSXO|YYm= MnzrNVAhdk1? MWK0M|YwOTZiaB?= NELWPVZqdmS3Y3XzJJRp\SCpZX7ldoF1cW:wIH;mJIh6\HKxZ3XuJJBmem:6aXTlJIZzd21iNHi= NFruZ5IzODZ{NEG2Ny=>
HP100 NX3pTmZXTnWwY4Tpc44hSXO|YYm= NInmUnoyOCCwTR?= NITOdms1NzZxMU[gbC=> M1jLbYlv\HWlZYOgeIhmKGenbnXyZZRqd25ib3[gbJllem:pZX6gdIVzd3irZHWg[pJwdSB2aB?= MWKyNFYzPDF4Mx?=
HL-60  NXLrcIdoTnWwY4Tpc44hSXO|YYm= M3\UPVExNTVyMDDuUS=> MljaOEBp NXXxWHR{\GWlcnXhd4V{KHSqZTDobZN1d26nIHTlZYNmfHmuYYPlJEhJTEGFKTDhZ5Rqfmm2edMg NF7ifI8zODZ{NEG2Ny=>
HP100 NUDhVFBvTnWwY4Tpc44hSXO|YYm= M17BblExNTVyMDDuUS=> MYW0JIg> M2\aWIRm[3KnYYPld{B1cGViaHnzeI9v\SCmZXHj[ZR6dGG|ZTCoTGRCSyliYXP0bZZqfHoEoB?= NXHhUI1UOjB4MkSxOlM>
11z NWPxcJduU2mwYYPlJGF{e2G7 MlTpN{0yODBibl2= NFHaOodz\WS3Y3XzJGhFSUNiZX76fY1ifGmlIHHjeIl3cXS7IDjJR|UxyqB;IE[uOUDDuSByLk[gco1wdC:OKR?= M3vDWlIxPjB3MUS0
SKOV-3 NFTpfnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3e2O|QwQC9zNjDuUS=> NXm3V3FmPDhiaB?= NXvnWI9KcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XJ? NHLkVJUzODRyNEW2OC=>
OVCAR-3 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVm0M|gwOTZibl2= NYf6XWk2PDhiaB?= NI\yRWxqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5meg>? NVjpdoVWOjB2MES1OlQ>
HBL-2 M2L6W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWWyMVExKG6P MorvNlQhcA>? MlPwTWM2OD12LkOgcm0> NYruVGt4OjByNkiwPFA>
Jeko-1 M3u4e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUmyMVUxKG6P MXWyOEBp M1XnW2lEPTB;MUGgcm0> M4Hxd|IxODZ6MEiw
Granta-519 NFPLcotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDwS3U2NTRyIH7N NHv1Z3gzPCCq NUnDcHZ[UUN3ME21PE42KG6P NGruO28zODB4OEC4NC=>
L1236 NU[4TnhXS3m2b4TvfIlkcXS7IFHzd4F6 NGft[VgyKG6PLUGwNEDPxE1? MVu0PEBp NWP0OWhQTUN3ME2wMlA4KM7:TR?= NFLTdlQyQTJ|M{S3NC=>
L428 MofiR5l1d3SxeHnjbZR6KEG|c3H5 MXixJI5ONTFyMDFOwG0> MknsOFghcA>? NX3sfFVCTUN3ME2wMlQ{KM7:TR?= Mn2wNVkzOzN2N{C=
KM-H2 NUfGS4QxS3m2b4TvfIlkcXS7IFHzd4F6 MkLWNUBvVS1zMECg{txO NEfDOIM1QCCq MnixSWM2OD1yLkW4JO69VQ>? NUC5bXlLOTl{M{O0O|A>
L540Cy MV\DfZRwfG:6aXPpeJkhSXO|YYm= NWiyT4FjOSCwTT2xNFAh|ryP MVm0PEBp NVj1ZVg4TUN3ME2wMlE3KM7:TR?= NWLNZokxOTl{M{O0O|A>
G401 NXS4[FdmTnWwY4Tpc44hSXO|YYm= MW[xNEBvVQ>? NYq5SFlMOjRxNEivO|IhcA>? NX33WJhxTE2VTx?= NUeydlc6cW6lcnXhd4V{KEOGS16xR{BmgHC{ZYPzbY9v NIH5XFkyQTJ{MUW4Oi=>
STM91-01 NXzuUYhSTnWwY4Tpc44hSXO|YYm= Ml;hNVAhdk1? MVqyOE81QC95MjDo NETFeWlFVVOR NIDZcHRqdmO{ZXHz[ZMhS0SNTkHDJIV5eHKnc4Ppc44> Mo\KNVkzOjF3OE[=
SJSC  NEDHR2ZHfW6ldHnvckBCe3OjeR?= MWmxNEBvVQ>? M4DWUFI1NzR6L{eyJIg> NFTOe5lFVVOR Ml3obY5kemWjc3XzJGNFU05zQzDlfJBz\XO|aX;u MV6xPVIzOTV6Nh?=
BT16  NFzRT2RHfW6ldHnvckBCe3OjeR?= MUOxNEBvVQ>? MVyyOE81QC95MjDo Ml\iSG1UVw>? NGP4R4lqdmO{ZXHz[ZMhS0SNTkHDJIV5eHKnc4Ppc44> NGDHPZEyQTJ{MUW4Oi=>
NCI-H1299 NILOOG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVq0fllnUUN3ME20MlbDuTBwMjDu[{9udA>? M3TPVlE6OTd7OEmw
NCI-2882 M{SzOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37CRmlEPTB;MT62xtExNjB2IH7nM41t M1nPe|E6OTd7OEmw
HCC95 M2XFZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTJwNdMxNE4xPSCwZz;tcC=> MYGxPVE4QTh7MB?=
NCI-H23 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGP6UlJKSzVyPUKuPeKyOC5{IH7nM41t MkjSNVkyPzl6OUC=
NCI-H157 Mn3CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnu3TWM2OD1zLkdCtVAvODJibnevcYw> MnXBNVkyPzl6OUC=
NCI-H460 NYPoeHpjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;ZeWlEPTB;Mj6xxtExNjB5IH7nM41t MknENVkyPzl6OUC=
NCI-H1975 NYPXWJNLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\rV24yUUN3ME2xMlPDuTBwMESgcocwdWx? MXuxPVE4QTh7MB?=
NCI-H820 MkLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHr1dVFKSzVyPUKuOOKyOC5zIH7nM41t MkDLNVkyPzl6OUC=
NCI-H1650 MoXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTRwOdMxNE4{KG6pL33s M{PseVE6OTd7OEmw
DTC1 Mn;QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrJTWM2OD1yLkWxJI5O M33BcVE5PTZ4MkS2
KAO NFG4OJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGr3XnVKSzVyPUCuPVEhdk1? NVHqU3R4OTh3Nk[yOFY>
SU-CCS-1 M3HoSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjtNWJHUUN3ME2wMlg6KG6P NV3MPG9WOTh3Nk[yOFY>
SYO-1 NYewSIdOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\wbWlEPTB;MD62O{BvVQ>? MUexPFU3PjJ2Nh?=
FUJI MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfvTWM2OD1zLkOxJI5O NF7HXFIyQDV4NkK0Oi=>
SKNMC MlnIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnIR|dFUUN3ME2xMlE4KG6P NHXqc4MyQDV4NkK0Oi=>
402-91 NIHocYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTFwMk[gcm0> Mom5NVg2PjZ{NE[=
1765-92 M123Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;LZ3hKSzVyPUGuO|chdk1? MYWxPFU3PjJ2Nh?=
JN-DSRCT-1 NUf0O4ExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\T[mlEPTB;MT6yOUBvVQ>? Mo[5NVg2PjZ{NE[=
NMS-2PC NFv1SIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTBwOEGgcm0> MUmxPFU3PjJ2Nh?=
HL60 M2DwOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTFwOE[gcm0> M1\TU|E5PTZ4MkS2
A549 Ml\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYr6c4ZFUUN3ME2zMlI1KG6P MlfZNVg2PjZ{NE[=
SW480 NE\wOZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjqfFdvUUN3ME2yMlY6KG6P NYnHUnp7OTh3Nk[yOFY>
MCF7 Mln5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fuemlEPTB;Mz61OUBvVQ>? NX7zdW1KOTh3Nk[yOFY>
PC-3 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfmcJJKSzVyPUKuOVEhdk1? M4fUO|E5PTZ4MkS2
MMRU MljHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHKXoZKSzVyPUKuOVchdk1? NHzNPYoyQDV4NkK0Oi=>
Hs68 M3nyNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnOTWM2OD1-MUCgcm0> MXqxPFU3PjJ2Nh?=
hMSC-001F MkTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn:5TWM2OD1-MUCgcm0> NEjRXWQyQDV4NkK0Oi=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p21 / Cyclin D1; 

PubMed: 19682393     


NIH 3T3 cells stably expressing the indicated proteins were treated with DMSO (Vehicle) or the indicated concentration of romidepsin for 24 h. Cell lysates were analyzed by western blotting with antibodies to cyclin D1, p21 and β-actin (loading control). Data shown are representative of at least two independent experiments.

AcH3(K9) / Ac-α-Tubulin(K40) / Ac-NFκB2(K310) p65 / 3MeH3(K27); 

PubMed: 26473529     


Effects of romidepsin (Rom) on the levels of acetylated proteins and related enzymes. Cells were exposed to romidepsin for 48 h and total cell extracts were analyzed by western blot.

HDAC3 / HDAC4 / HDAC6 / HDAC2; 

PubMed: 26473529     


Effects of romidepsin (Rom) on the levels of acetylated proteins and related enzymes. Cells were exposed to romidepsin for 48 h and total cell extracts were analyzed by western blot.

γH2AX / PARP1 / Cleaved caspase3 / BAK / p21(waf1/cip1) / XIAP; 

PubMed: 26473529     


Western blot analysis of proteins involved in DNA-damage response and apoptosis. Established cell lines were exposed to different concentrations of romidepsin (Rom) for 48 h and total cell extracts were analyzed.

Cyclin E1 / BRCA1 / E2F1 / Cleaved PARP / H3Ac; 

PubMed: 27444036     


Western blot analysis of the effects of panobinostat (25 nM), vorinostat (5 µM) and romidepsin (10 nM) on expression of cyclin E1, E2F1, BRCA1, cleaved PARP and acetylated histone H3 in OVCAR-3 cells. Actin and histone H3 were loading controls. 

pAKT(S473) / pAKT(T308) / AKT; 

PubMed: 25492515     


Western blot analysis of phosphorylated AKT in PC3 cells. Cells were treated for 3 h with various concentrations of FK228. 

19682393 26473529 27444036 25492515
Growth inhibition assay
Cell viability; 

PubMed: 27444036     


Concentration-dependent effects of panobinostat and vorinostat in SRB viability assays in OVCAR-3 cells (72 h). Values are mean+SE of 3 independent experiments. 

27444036
Immunofluorescence
SS18/TLE1; 

PubMed: 27120803     


A significant decrease in detectable PLA signal following HDAC inhibition in SYO-1 cells.

Cleaved caspase-3; 

PubMed: 22531354     


TDP-B activates cleaved caspase-3 by immunofluorescence. Representative immunofluorescence staining for cleaved caspase 3 (green) in SKOV-3 ovarian cancer cells treated with 10 nM FK228, TDP-A or TDP-B after 24 h of exposure. The nuclei are stained with DAPI (blue).

27120803 22531354
In vivo Romidepsin treatment potently inhibits the neovascularization of chick embryo and that of adult mice in the Matrigel plug assay. [4]Administration of Romidepsin at 0.1-1 mg/kg twice a week significantly prolongs the survival of mice bearing U-937 lymphoma, with median survival times of 30.5 (0.56 mg/kg) and 33 days (0.32 mg/kg), respectively (vs. 20 days in control mice). [5]

Protocol

Kinase Assay:

[1]

- Collapse

HDAC-inhibitory activity:

For the enzyme assay, 10 μL of [3H]acetyl-labeled histones (25,000 cpm/10 μg) are added to 90 μL of the HDAC enzyme fraction extracted from 293T cells overexpressing HDAC1 or HDAC2 in the presence of increasing concentrations of Romidepsin, and the mixture is incubated at 37 °C for 15 minutes. The enzyme reaction is linear for at least 1 hour. The reaction is stopped by the addition of 10 μL of concentrated HCl. The released [3H]acetic acid is extracted with 1 mL of ethylacetate, and 0.9 mL of the solvent layer is taken into 5 mL of aqueous counting scintillant II solution for determination of radioactivity. The IC50 values are determined from at least three independent dose-response curves.
Cell Research:

[3]

- Collapse
  • Cell lines: HL60, Jurkat, A549, and MCF-7
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are exposed to various concentrations of Romidepsin for 72 hours in 96-well plates. 20 μL of 5 mg/mL MTT solution in PBS is added to each well for 4 hours. After removal of the medium, 170 μL of DMSO is added to each well to dissolve the formazan crystals. The absorbance at 540 nm is determined. In addition, cells are incubated with trypan blue, and the numbers of blue (dead) cells and transparent (live) cells are counted in a hemocytometer. For cell cycle analysis, cells are incubated for 30 minutes in propidium iodide staining solution containing 0.05 mg/mL propidium iodide, 1 mM EDTA, 0.1% Triton X-100, and 1 mg/mL RNase A in PBS. The suspension is then passed through a nylon mesh filter and analyzed on a Becton Dickinson FACScan.


    (Only for Reference)
Animal Research:

[5]

- Collapse
  • Animal Models: Male scid mice inoculated i.p. with U-937 cells
  • Dosages: ~1 mg/kg once or twice a week
  • Administration: Treated i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 10 mg/mL (18.49 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+5%Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 540.7
Formula

C24H36N4O6S2

CAS No. 128517-07-7
Storage powder
in solvent
Synonyms FR 901228, NSC 630176

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03770000 Recruiting Drug: Tenalisib|Drug: Romidepsin T Cell Lymphoma Rhizen Pharmaceuticals SA March 12 2019 Phase 1|Phase 2
NCT02616965 Recruiting Drug: Romidepsin|Drug: Brentuximab vedotin Cutaneous T-cell Lymphoma (CTCL) Fox Chase Cancer Center|Seattle Genetics Inc.|Celgene Corporation February 22 2017 Phase 1
NCT02616874 Completed Drug: MVA.HIVconsv vaccine|Drug: Romidepsin HIV IrsiCaixa|Germans Trias i Pujol Hospital|Fundacio Lluita Contra la SIDA|Hospital Clinic of Barcelona|Hospital de Sant Pau|HIVACAT|University of Oxford|BCN Checkpoint February 2016 Phase 1
NCT03141203 Active not recruiting Drug: Romidepsin|Drug: Carfilzomib Peripheral T Cell Lymphoma University of Birmingham|Bloodwise|Celgene|Amgen July 13 2015 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide) supplier | purchase Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide) cost | Romidepsin (FK228, Depsipeptide) manufacturer | order Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID